Kospi rally cools Korea crypto trading
South Korea's cryptocurrency market has slowed markedly as retail investors shift funds into equities, with the Kospi reaching fresh record highs while crypto trading activity weakens.

TV presenter and finance editor at Grafa, with a Master’s in Commerce from UWA and diverse industry experience in finance, insurance, and media.
South Korea's cryptocurrency market has slowed markedly as retail investors shift funds into equities, with the Kospi reaching fresh record highs while crypto trading activity weakens.
Fast-food giant Collins Foods (ASX:CKF) finalised its acquisition of eight KFC restaurants across Bavaria, Germany.
The team behind President Donald Trump’s meme coin has unveiled a new loyalty programme called the Trump Coin Club, aimed at providing exclusive experiences and benefits to the token’s largest holders.
Brussels-based digital asset services firm Keyrock has agreed to acquire certain assets of bankrupt crypto trading and lending company BlockFills for $3.25 million, subject to court and regulatory approval.
Aura Energy (ASX:AEE) secured a milestone for its Tiris Uranium Project, signing a n MOU with an international nuclear utility.
Swan Bitcoin’s lawsuit against Proton Management and several former employees was dismissed by a California federal judge on June 1 after Swan conceded in related UK proceedings that it never owned the mining assets and trade secrets underpinning its claims.
Elliott Investment Management takes a $1b stake in Northern Star Resources (ASX:NST), demanding a review and external CEO.
Credo Technology Group Holding (NASDAQ:CRDO) reported its financial and operating results for the fourth quarter and full fiscal year 2026 ended May 2, 2026, delivering triple-digit top-line expansion fueled by accelerated global demand for high-speed, energy-efficient data connectivity infrastructure.
Worldcoin gained as much as 8% after World Network announced a partnership with Thirty Seconds to Mars that uses World ID technology to provide human-only access to selected concert ticket sales.
IDEAYA Biosciences (NASDAQ:IDYA) and Servier reported complete data Monday from the primary analysis of their registrational Phase 2/3 OptimUM-02 clinical trial.